Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Type
(
1 selected
)
Type
Guidance (17)
Guidance programme
(
1 selected
)
Guidance programme
Technology appraisal guidance (17)
Apply filters
Showing 1 to 17 of 17
breast cancer
Remove breast cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative
breast cancer
ID 6200
Technology appraisal guidance
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early
breast cancer
[ID6152]
Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with
breast cancer
TS ID 11769
Technology appraisal guidance
Capivasertib with paclitaxel for untreated metastatic triple-negative
breast cancer
[ID6383]
Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative
breast cancer
[ID6435]
Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced
breast cancer
[ID 5072]
Technology appraisal guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic
breast cancer
TS ID 11990
Technology appraisal guidance
Palbociclib for treating high-risk early
breast cancer
after neoadjuvant chemotherapy [ID3846]
Technology appraisal guidance
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic
breast cancer
[ID6251]
Technology appraisal guidance
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic
breast cancer
[ID6285]
Technology appraisal guidance
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early
breast cancer
[ID3993]
Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced
breast cancer
ID6433
Technology appraisal guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early
breast cancer
TS ID 11910
Technology appraisal guidance
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic
breast cancer
after 2 or more endocrine treatments [ID6226]
Technology appraisal guidance
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic
breast cancer
after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]
Technology appraisal guidance
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced
breast cancer
after induction chemotherapy [ID6402]
Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced
breast cancer
after a taxane, trastuzumab or both together TS ID 11781
Technology appraisal guidance
Current page
1
Page
1
of
1
Results per page
10
25
50
All
Back to top